Callan Family Office LLC Buys New Stake in Globe Life Inc. $GL

Callan Family Office LLC acquired a new stake in shares of Globe Life Inc. (NYSE:GL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 2,979 shares of the company’s stock, valued at approximately $532,000.

Several other large investors have also recently made changes to their positions in GL. Hilton Head Capital Partners LLC bought a new position in Globe Life during the fourth quarter valued at approximately $30,000. Johnson Financial Group Inc. bought a new stake in Globe Life in the 2nd quarter worth approximately $39,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Globe Life during the 2nd quarter worth approximately $28,000. MUFG Securities EMEA plc purchased a new stake in shares of Globe Life during the 2nd quarter worth approximately $31,000. Finally, Torren Management LLC bought a new position in shares of Globe Life during the 4th quarter valued at approximately $37,000. 81.61% of the stock is owned by institutional investors.

Globe Life Trading Down 0.4%

Shares of GL stock opened at $172.44 on Wednesday. The company has a market cap of $13.25 billion, a PE ratio of 11.45 and a beta of 0.48. Globe Life Inc. has a 1 year low of $127.85 and a 1 year high of $191.55. The stock’s 50 day simple moving average is $178.54 and its two-hundred day simple moving average is $159.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.07 and a quick ratio of 0.07.

Globe Life (NYSE:GL) last announced its earnings results on Wednesday, July 22nd. The company reported $3.61 EPS for the quarter, missing analysts’ consensus estimates of $3.67 by ($0.06). The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Globe Life had a return on equity of 20.52% and a net margin of 19.58%.Globe Life’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.05 EPS. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. Research analysts predict that Globe Life Inc. will post 15.71 earnings per share for the current year.

Globe Life Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Monday, October 5th will be given a $0.33 dividend. The ex-dividend date is Monday, October 5th. This represents a $1.32 dividend on an annualized basis and a yield of 0.8%. Globe Life’s dividend payout ratio (DPR) is currently 8.76%.

Globe Life announced that its Board of Directors has initiated a stock buyback program on Monday, August 10th that permits the company to repurchase $2.50 billion in shares. This repurchase authorization permits the company to reacquire up to 17.7% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Weiss Ratings lowered shares of Globe Life from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, July 20th. JPMorgan Chase & Co. upped their price target on shares of Globe Life from $181.00 to $201.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Jefferies Financial Group increased their price objective on shares of Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a research report on Friday, July 10th. Wells Fargo & Company boosted their target price on shares of Globe Life from $172.00 to $193.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Piper Sandler boosted their target price on shares of Globe Life from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globe Life currently has a consensus rating of “Moderate Buy” and an average price target of $191.67.

Insider Activity at Globe Life

In other Globe Life news, CEO Frank M. Svoboda sold 10,000 shares of Globe Life stock in a transaction on Friday, June 12th. The shares were sold at an average price of $166.68, for a total transaction of $1,666,800.00. Following the completion of the transaction, the chief executive officer directly owned 54,020 shares of the company’s stock, valued at $9,004,053.60. The trade was a 15.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Clay Majors sold 37,000 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $178.64, for a total transaction of $6,609,680.00. Following the transaction, the executive vice president owned 53,518 shares in the company, valued at $9,560,455.52. This trade represents a 40.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 151,908 shares of company stock valued at $27,239,981 over the last three months. Corporate insiders own 2.11% of the company’s stock.

Globe Life Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.